BL Pharmtech Sells Entire Stake in KwangdongHealthbio for 2.6 Billion Won… "To Strengthen Liquidity"
Transferred approximately 1.77 million shares to Guangdong Life Health… Stake reduced to 0%
Sale Proceeds Amount to 25.7% of Equity… Payment to Be Received on January 4 Next Year
[Edaily Reporter KIM SAE-MI ] BL Pharmtech(065170)is selling its entire stake in KwangdongHealthbio for approximately 2.6 billion won to strengthen its liquidity.
BL Pharmtech CI (Photo: BL Pharmtech) BL Pharmtech announced on the 5th that it has decided to transfer 1,770,958 shares of KwangdongHealthbio to Guangdong Lifestyle Health for 2,553,140,000 won.
The transfer amount represents 14.03% of the company’s total assets of 18.2 billion won and 25.72% of its equity of 9.9 billion won, as reported on a consolidated basis at the end of last year. The transfer price was calculated based on the net asset value reported in the externally audited financial statements, and no separate external valuation was conducted.
Following this transaction, BL Pharmtech’s stake in KwangdongHealthbio will be reduced to 0%. The full purchase price is scheduled to be paid in cash on January 4 of next year.
An official from BL Pharmtech stated, “The purpose of the sale is to strengthen liquidity.”
Meanwhile, KwangdongHealthbio is a manufacturer and importer/exporter of health functional foods; last year, it posted revenue of 67 billion won and a net loss of 600 million won. As of the end of last year, its total assets stood at 62.2 billion won, and total liabilities at 43.9 billion won.
The slump in the non-investment-grade corporate bond market—which has been centered on BBB-rated bonds this year—is expected to spread to A-rated companies next year. As the burden of issuing corporat…
Amid broader market volatility on Thursday, South Korea’s biopharmaceutical sector lacked a clear directional trend, leaving traditional, profitable pharmaceutical and biotech firms to anchor investor…
A forecast indicates that U.S. production of humanoid robots will reach up to 400,000 units by 2030 and 1.5 million units by 2035. Analysts predict that as the humanoid robot industry moves beyond tec…